Kennedy Ferruggia, Associate Editor

Careful history, adherence support, and proper medication technique are central to diagnosing and managing chronic cough in children.

Social determinants of health and environmental exposures during extreme weather events worsen asthma outcomes.

Learn how COVID-19 drives heart and vascular risks, why vaccines and antivirals help, and how pharmacists manage dangerous drug interactions.

Managing high-cost oncology therapies requires extensive cross-functional coordination, with pharmacists playing a central role.

FDA clears pegzilarginase-nbln enzyme therapy for ARG1-D, cutting toxic arginine and boosting mobility.

FDA approves once-daily oral Wegovy for weight loss and long-term maintenance, matching injectable results while cutting cardiovascular event risk.

Pharmacists boost late-season flu, COVID-19, and RSV vaccination with coadministration guidance, fatigue-fighting messaging, and community access strategies.

The FDA accepts Moderna’s mRNA flu vaccine filing, targeting adults 50 years and older, with an accelerated path for older adults and a 2026 decision deadline.

Allison Hill, PharmD, RPh, underscores how pharmacists can sustain vaccination momentum through community partnerships.

Craig Beavers, PharmD, explores new phase 3 evidence on factor XIa inhibitors for secondary stroke prevention, highlighting OCEANIC-STROKE results, safety, and patient selection.

Allison Hill, PharmD, RPh, emphasizes that it is not too late for flu vaccination and highlights how pharmacists can address vaccine fatigue.

Registry data show COVID-era care disruptions cut 1-year cancer survival, adding 17,390 excess deaths—the biggest losses in late-stage and older patients.

Shifting federal vaccine guidance fuels parent confusion and uneven care, as clinicians lean on scientific consensus.

The FDA targets mass-marketed compounded GLP-1 drugs, warning of safety risks and deceptive ads as enforcement ramps up for weight-loss injectables.

The FDA declines to review Moderna’s mRNA flu vaccine filing over comparator choice, despite positive phase 3 results.

Learn how pharmacists cut GLP-1 costs, streamline prior authorizations, guide safe switches, and bust social media myths for lasting adherence.

Host Craig Beavers explores why US blood pressure control still lags despite proven treatments.

Pharmacists are critical in supporting GLP-1 therapy success through proactive expectation setting.

Bangladesh reports fatal Nipah case linked to raw date palm sap; experts say spread stays limited as vaccines and rapid tests advance.

Learn how workplace triggers, long flares, and new therapies reshape pharmacist-led care for chronic hand eczema.

Ongoing variation in vaccine schedule implementation requires pharmacists and clinicians to collaborate closely, reinforce evidence-based care, and monitor vulnerable populations for gaps in immunization coverage.

Pharmacists play a vital role in countering GLP-1 misinformation.

India has confirmed 2 Nipah infections in West Bengal as surveillance tracks 196 contacts with no spread, with the World Health Organization outlining symptoms, transmission, and response measures.

Changes to the federal childhood vaccine schedule have created confusion and variation in practice, placing added responsibility on clinicians and pharmacists to educate patients and ensure evidence-based care.

Phase 1 data show oral NSD2 inhibitor KTX-1001 delivers durable disease control in high-risk myeloma, with manageable thrombocytopenia and combo plans.

COVID-19 significantly impacts diagnosis rates for depression, asthma, and osteoporosis, revealing health care inequities and the need for improved monitoring.

KTX-1001, a novel oral inhibitor of NSD2, demonstrates early clinical activity and manageable safety in heavily pretreated multiple myeloma.

Pharmacists play a critical role in improving access to and affordability of GLP-1 therapies.

Research reveals that patients with asthma who experience symptoms of depression show elevated BDNF levels, suggesting unique biological links between asthma severity and depressive symptoms.

RegeneCyte's HPC therapy shows promise in treating long COVID symptoms, with 85% of patients reporting fatigue relief.